[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100502843":3},{"organization":4,"outcomesModule":7,"designInfo":42,"detailedDescription":52,"studyPopulation":11,"armGroups":53,"interventions":64,"overallOfficials":11,"centralContacts":70,"locations":76,"responsibleParty":149,"collaborators":11,"id":151,"slug":11,"hasResults":152,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":152,"sex":158,"minAge":159,"maxAge":160,"enrollmentInfo":161,"targetDuration":11,"studyType":164,"phases":165,"briefSummary":167,"conditions":168,"keywords":170,"overallStatus":87,"whyStopped":11,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":189},{"fullName":5,"class":6},"National Cancer Center, Korea","OTHER_GOV",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Overall survival (OS)",null,"From randomization to the date of death from any cause, assessed up to 5 years",[14,17,20,24,28,32,35,38],{"measure":15,"description":11,"timeFrame":16},"Progression-free survival (PFS)","From randomization to time of first progression or death from any cause, whichever came first, assessed up to 5 years",{"measure":18,"description":11,"timeFrame":19},"Cancer-specific survival","From randomization to the date of death due to ovarian cancer, assessed up to 5 years",{"measure":21,"description":22,"timeFrame":23},"Time to first subsequent therapy (TFST)","the interval from the last day of the last cycle of a prior regimen of chemotherapy to the first day of the first cycle of the subsequent regimen for each course of chemotherapy","from the last day of the last cycle of a prior regimen of chemotherapy to the first day of the first cycle of the subsequent chemotherapy, assessed up to 5 years",{"measure":25,"description":26,"timeFrame":27},"Treatment-related adverse events","assessed by CTCAE ver.5.0","From randomization up to the end of treatment plus 4 weeks",{"measure":29,"description":30,"timeFrame":31},"Health-related quality of life (EORTC-QLQ-C30)","The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status.","Over the 5 year surveillance period",{"measure":33,"description":34,"timeFrame":31},"Health-related quality of life (EORTC-QLQ-OV28)","The EORTC QLQ-OV28 is a specified questionnaire for patients with ovarian cancer. Participant responses to the question are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized so that scores range from 0 to 100. A lower score indicates a better outcome.",{"measure":36,"description":37,"timeFrame":31},"Health-related quality of life (EQ-5D-5L)","Each dimension in the EQ-5D-5L has five response levels: no problems (Level 1); slight; moderate; severe; and extreme problems (Level 5).",{"measure":39,"description":40,"timeFrame":41},"Cost-effectiveness analysis","assessed by Quality-Adjusted Live Years (QALYs), incremental cost-effectiveness ratio (ICER)","At time of completion of 5-year surveillance period",{"allocation":43,"interventionModel":44,"interventionModelDescription":45,"primaryPurpose":46,"observationalModel":11,"timePerspective":11,"maskingInfo":47},"RANDOMIZED","PARALLEL","Randomized controlled, single-blinded, multicenter phase III trial","TREATMENT",{"masking":48,"maskingDescription":49,"whoMasked":50},"SINGLE","Enrolled patients are unaware of which group they have been assigned to.",[51],"PARTICIPANT","The goal of this phase III randomized controlled trial is to compare the clinical efficacy of HIPEC with cisplatin (trial arm) compared to no HIPEC (control arm) during interval cytoreductive surgery followed by neoadjuvant chemotherapy, in patients with stage III-IV primary epithelial ovarian cancer.",[54,60],{"label":55,"type":56,"description":57,"interventionNames":58},"HIPEC","EXPERIMENTAL","Interval cytoreductive surgery with HIPEC",[59],"Drug: Cisplatin",{"label":61,"type":62,"description":63,"interventionNames":11},"No HIPEC","NO_INTERVENTION","Interval cytoreductive surgery without HIPEC",[65],{"type":66,"name":67,"description":68,"armGroupLabels":69,"otherNames":11},"DRUG","Cisplatin","Hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin 75mg\u002Fm2 after interval cytoreductive surgery",[55],[71],{"name":72,"role":73,"phone":74,"phoneExt":11,"email":75},"Myong Cheol Lim, MD, Ph.D","CONTACT","+820319201760","gynlim@gmail.com",[77,83,85,96,110,118,126,131,139,144],{"facility":78,"status":79,"city":80,"state":81,"zip":11,"country":82,"countryCode":11,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"Chungnam National University Hospital","NOT_YET_RECRUITING","Sejong","Chungcheongnam-do","South Korea",{"facility":84,"status":79,"city":80,"state":81,"zip":11,"country":82,"countryCode":11,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"Chungnam National University Sejong Hospital",{"facility":86,"status":87,"city":88,"state":89,"zip":11,"country":82,"countryCode":11,"cosmosGeoPoint":90,"geoPoint":95,"contacts":11},"Ilsan CHA University Hospital","RECRUITING","Goyang-si","Gyeonggi-do",{"type":91,"coordinates":92},"Point",[93,94],126.835,37.65639,{"lat":94,"lon":93},{"facility":97,"status":87,"city":88,"state":89,"zip":11,"country":82,"countryCode":11,"cosmosGeoPoint":98,"geoPoint":100,"contacts":101},"National Cancer Center",{"type":91,"coordinates":99},[93,94],{"lat":94,"lon":93},[102,104,107],{"name":103,"role":73,"phone":74,"phoneExt":11,"email":75},"Myong Cheol Lim, MD, PhD",{"name":105,"role":73,"phone":11,"phoneExt":11,"email":106},"Ji Hyun Kim, MD","gynlittle@gmail.com",{"name":108,"role":109,"phone":11,"phoneExt":11,"email":11},"Myong Cheol Lim","PRINCIPAL_INVESTIGATOR",{"facility":111,"status":87,"city":112,"state":89,"zip":11,"country":82,"countryCode":11,"cosmosGeoPoint":113,"geoPoint":117,"contacts":11},"Ajou University Hospital","Suwon",{"type":91,"coordinates":114},[115,116],127.00889,37.29111,{"lat":116,"lon":115},{"facility":119,"status":79,"city":120,"state":11,"zip":11,"country":82,"countryCode":11,"cosmosGeoPoint":121,"geoPoint":125,"contacts":11},"Pusan National University Hospital","Pusan",{"type":91,"coordinates":122},[123,124],128.02524,35.70128,{"lat":124,"lon":123},{"facility":127,"status":79,"city":120,"state":11,"zip":11,"country":82,"countryCode":11,"cosmosGeoPoint":128,"geoPoint":130,"contacts":11},"Pusan National University Yangsan Hospital",{"type":91,"coordinates":129},[123,124],{"lat":124,"lon":123},{"facility":132,"status":79,"city":133,"state":11,"zip":11,"country":82,"countryCode":11,"cosmosGeoPoint":134,"geoPoint":138,"contacts":11},"Asan Medical Center","Seoul",{"type":91,"coordinates":135},[136,137],126.9784,37.566,{"lat":137,"lon":136},{"facility":140,"status":79,"city":133,"state":11,"zip":11,"country":82,"countryCode":11,"cosmosGeoPoint":141,"geoPoint":143,"contacts":11},"Ewha Womans University Mokdong Hospital",{"type":91,"coordinates":142},[136,137],{"lat":137,"lon":136},{"facility":145,"status":87,"city":133,"state":11,"zip":11,"country":82,"countryCode":11,"cosmosGeoPoint":146,"geoPoint":148,"contacts":11},"Severance Hospital",{"type":91,"coordinates":147},[136,137],{"lat":137,"lon":136},{"type":109,"investigatorFullName":103,"investigatorTitle":150,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Principal Researcher","100502843",false,"NCT05827523","Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS \u002F KOV-HIPEC-04)","Phase III Randomized Trial of HIPEC in Primary Stage Three & Four Primary Ovarian Cancer After Interval Cytoreductive Surgery (FOCUS, KOV-04)","FOCUS \u002F KOV-04","Inclusion Criteria:\n\n1. Signed and written informed consent,\n2. Patients ≥18, \\\u003C80 years old,\n3. Diagnosed with histologically confirmed FIGO stage III-IV primary epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer treated with three cycles of neoadjuvant chemotherapy,\n4. Treated with interval complete cytoreduction, or cytoreduction with no more than 2.5 mm depth of residual disease,\n5. A life expectancy \\> 3 months as clinically judged,\n6. Adequate organ function for cytoreductive surgery and HIPEC,\n7. Women who are medically unable to conceive or who are of childbearing potential, agree to follow contraceptive guidelines during treatment and,\n8. Patients can also consent to the provision of clinical information for secondary use, such as future biomedical research. However, in the future, subjects can participate in the main trial even if they do not intend to participate in sharing clinical information.\n\nExclusion Criteria:\n\n1. Diagnosed with non-epithelial ovarian carcinoma or borderline ovarian tumor\n2. Patients who have not undergone neoadjuvant chemotherapy,\n3. Interval cytoreduction with more than 2.5 mm depth of residual disease,\n4. A life expectancy ≤3 months as clinically judged,\n5. History of previous malignancy within five years prior to inclusion, that affects ovarian cancer treatment results, with the exception of carcinoma in situ, radically excised basal cell or squamous cell cancer of the skin, or synchronal endometrial carcinoma FIGO IA G1\u002F2,\n6. Patients with myelodysplastic syndrome (MDS)\u002Facute myeloid leukemia (AML) or with features suggestive of MDS\u002FAML,\n7. Patients with active central nervous system metastasis and carcinoma meningitis or patients who have been previously treated for brain metastases must be in a stable state in radiology,\n8. Patients with antibacterial, antifungal, or antiviral infections requiring systemic treatment (administration of parenteral antibiotics),\n9. Active tuberculosis that is not controlled within 1 month of treatment,\n10. Patients diagnosed with a psychiatric disorder or substance abuse disorder that would interfere with your ability to cooperate with the trial,\n11. Patients with any contraindications to the use of cisplatin (i.e., hypersensitivity to cisplatin),\n12. Patients with a history of allogeneic tissue\u002Fsolid organ transplantation or bone marrow transplantation or a history of double umbilical cord transplantation or,\n13. History or current evidence of any condition, therapy, or laboratory abnormality that may confound the results of the study, or interfere with the patient's participation, in the opinion of the treating investigator.","ALL","18 Years","80 Years",{"count":162,"type":163},520,"ESTIMATED","INTERVENTIONAL",[166],"PHASE3","Primary stage III-IV epithelial ovarian cancer randomizing between interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC)",[169],"Ovarian Cancer",[171,172,55,173,174,175,176,177,178,179],"Ovarian cancer","Hyperthermic intraperitoneal chemotherapy","Interval cytoreductive surgery","Neoadjuvant chemotherapy","Carcinoma, Ovarian Epithelial","Epithelial ovarian cancer","FOCUS","kov-hipec-04","kov-04","2026-02-11",{"date":182,"type":183},"2026-02-13","ACTUAL",{"date":185,"type":183},"2023-05-31",{"date":187,"type":163},"2030-12-31",{"name":5,"class":6},10]